Molecular Partners presents Radio-DARPins at GRC
Analysis based on 6 articles · First reported Jul 15, 2026 · Last updated Jul 15, 2026
The presentation reinforces Molecular Partners' position in the radiopharmaceutical space, potentially boosting investor confidence in its pipeline. However, as a clinical-stage biotech, the immediate market impact is limited, with attention focused on upcoming trial data and program announcements.
On July 15, 2026, Molecular Partners AG presented its multispecific Radio-DARPin approaches at the Gordon Research Conferences on Radionuclide Theranostics for the Management of Cancer in Newry, Maine, US. The presentation, titled 'Appropriate Targets for RLT? High selectivity vs high expression', was delivered by Daniel Steiner, Ph.D., SVP of Targeted Radio Therapeutics. The company highlighted its development of bispecific and DuoDARPin formats to address tumor heterogeneity in radioligand therapy. Molecular Partners' lead candidate MP0712, co-developed with Orano, is in a US Phase 1/2a trial, while MP0726 is advancing toward first human imaging. A third Radio-DARPin program is expected to be announced in 2026. The company also has partnerships with Eckert & Ziegler and Pantera Capital for radiopharmaceutical manufacturing and isotope supply.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard